Cost Is the Biggest Barrier to Xifaxan Adherence

Xifaxan (Rifaximin) is a clinically effective, well-tolerated medication for hepatic encephalopathy (HE) and irritable bowel syndrome with diarrhea (IBS-D). But at $1,600 to $2,200 per month without insurance, cost is the single most common reason patients don't fill — or stop filling — their prescriptions. For HE patients who need Xifaxan as ongoing maintenance therapy, non-adherence can lead to hospitalizations that cost the healthcare system far more than the medication itself.

As a prescriber, you're uniquely positioned to help patients navigate the financial landscape. This guide covers the savings programs, discount strategies, and cost conversations that can keep your patients on therapy.

What Patients Are Actually Paying

Understanding the real-world cost landscape helps frame the conversation:

• Cash price (no insurance): $1,600–$2,200 for a 30-day supply of 550 mg tablets (60 tablets).
• With commercial insurance: Varies widely by plan. Prior authorization is almost universally required. Most formularies place Xifaxan on Tier 3 or specialty tier, meaning copays of $50–$200+ per fill even with coverage.
• Medicare Part D: Covered but subject to formulary placement and prior authorization. Patients may face significant cost-sharing in the coverage gap ("donut hole"). Step therapy through Lactulose is commonly required for the HE indication.
• Uninsured patients: Face the full cash price. This is where patient assistance programs become critical.

There is no generic version of Xifaxan available in the United States as of 2026. Rifaximin remains patent-protected, and no FDA-approved generic alternatives exist.

Manufacturer Savings Programs

Xifaxan Instant Copay Savings Card

This is the most impactful tool for commercially insured patients:

• Eligible patients: Those with commercial (private) health insurance.
• Savings: Patients may pay as little as $0 out of pocket.
• Enrollment: Visit xifaxan.copaysavingsprogram.com or call 1-866-XIFAXAN (1-866-943-2926).
• Not eligible: Patients with government insurance (Medicare, Medicaid, VA, TRICARE).

Consider keeping enrollment information or printed cards in your office. Many patients don't know this program exists until you or your staff mention it. Having your team proactively share the enrollment link at the point of prescribing can significantly improve fill rates.

Bausch Health Patient Assistance Program

For uninsured or underinsured patients who cannot afford Xifaxan:

• Eligible patients: Those without insurance or with inadequate coverage who meet income criteria.
• What it provides: Free or reduced-cost medication directly from the manufacturer.
• How to apply: Contact Bausch Health directly or visit needymeds.org for application details.

Patient Access Network (PAN) Foundation

PAN Foundation provides copay assistance for underinsured patients, including those on Medicare. Funding availability varies, so check current program status at panfoundation.org.

Coupon and Discount Cards

For patients who don't qualify for manufacturer programs — or as a supplementary option — third-party discount cards can reduce out-of-pocket costs:

• GoodRx — Shows prices at nearby pharmacies and provides coupons. Prices for Xifaxan through GoodRx vary but can offer modest savings off the cash price.
• SingleCare — Another coupon aggregator that negotiates pharmacy discounts.
• RxSaver, Optum Perks, BuzzRx — Additional options worth checking for competitive pricing.

Important caveat: discount cards typically cannot be combined with insurance. They're most useful for uninsured patients or when the cash price with a discount card is lower than the insurance copay (which is rare for Xifaxan given its high cost).

For a comprehensive patient-facing guide to these options, direct patients to our Xifaxan savings and coupons guide.

Generic Alternatives and Therapeutic Substitution

Since no generic Rifaximin exists, true generic substitution isn't possible. However, therapeutic alternatives may be appropriate depending on the indication:

For Hepatic Encephalopathy

• Lactulose — The first-line and most cost-effective treatment for HE. Many insurers require a trial of Lactulose before approving Xifaxan. For patients who tolerate Lactulose well and remain episode-free, it may be sufficient as monotherapy. Cost: typically under $30/month.
• Neomycin — An older aminoglycoside antibiotic sometimes used for HE, though nephrotoxicity and ototoxicity concerns limit its long-term use. Significantly cheaper than Xifaxan.
• Lactulose + Xifaxan combination — The most evidence-supported regimen for preventing HE recurrence. If cost is prohibitive, consider optimizing Lactulose dosing before adding Xifaxan.

For IBS-D

• Eluxadoline (Viberzi) — An alternative mechanism (mu-opioid receptor agonist) for IBS-D. Cost is also significant but may be more accessible on some formularies.
• Alosetron (Lotronex) — A 5-HT3 antagonist approved for women with severe IBS-D. Restricted prescribing program required.
• Dietary and behavioral interventions — Low-FODMAP diet, peppermint oil, and cognitive behavioral therapy have evidence for IBS-D management and carry no medication cost.

For a patient-facing overview of these options, see Xifaxan alternatives.

Building Cost Conversations Into Your Workflow

Cost conversations shouldn't be an afterthought. Here's how to integrate them into your prescribing workflow:

1. Screen for Financial Barriers at the Point of Prescribing

A simple question — "Do you have concerns about the cost of this medication?" — can surface issues before they lead to non-adherence. Many patients won't volunteer cost concerns unless asked.

2. Involve Your Staff

Train medical assistants and front-desk staff to:

• Provide the Xifaxan copay card information at checkout
• Initiate prior authorization promptly (delays = unfilled prescriptions)
• Connect uninsured patients with the Bausch Health Patient Assistance Program

3. Document Prior Authorization Efficiently

Xifaxan almost always requires prior authorization. To streamline the process:

• Document previous Lactulose use (or intolerance) clearly in the chart for HE patients
• Include specific IBS-D diagnostic criteria (Rome IV) in authorization requests
• Use electronic prior authorization (ePA) when available through your EHR

4. Follow Up on Fill Status

If your system allows, check whether the patient actually filled the prescription within 7-14 days. If they didn't, a quick outreach call from your team can identify cost barriers and offer solutions before the patient gives up.

5. Consider Specialty Pharmacy Routing

For patients on long-term Xifaxan (especially HE), specialty pharmacies often provide:

• Better insurance coordination and prior authorization support
• Copay assistance enrollment help
• Refill reminders and adherence monitoring
• Home delivery

Directing prescriptions to a specialty pharmacy can reduce the administrative burden on your practice while improving patient access.

Helping Patients Find Xifaxan in Stock

Beyond cost, some patients face difficulty locating a pharmacy that stocks Xifaxan. Because of its high cost, not all retail pharmacies carry it routinely. Direct patients to Medfinder for providers or have them check Medfinder to locate pharmacies with current stock. For more detail, our provider's guide to finding Xifaxan in stock covers this topic in depth.

Final Thoughts

Xifaxan is a valuable medication — but only if patients can afford to take it consistently. The gap between clinical evidence and real-world adherence is often a financial one. By proactively addressing cost at the point of prescribing, leveraging manufacturer programs, and building efficient prior authorization workflows, you can help close that gap. Your patients are counting on you to prescribe the right medication and help them actually access it.

For additional provider resources, visit Medfinder for Providers. For information on Xifaxan supply and availability, see our provider shortage update.